Sugi Predict

Sugi Predict / Compounds / SCHEMBL19948978

SCHEMBL19948978

SCHEMBL19948978

CC(C)(C)OC(=O)N1CCCC=C1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 2/20 0.38
▸ P2RX7 Q99572 1/20 0.37
▸ KDM1A O60341 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ PRMT5 O14744 1/20 0.32
▸ WDR77 Q9BQA1 1/20 0.32
▸ AAK1 Q2M2I8 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ PDE4A P27815 1/20 0.31
▸ PDE4B Q07343 1/20 0.31
▸ PDE4C Q08493 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ MAPT P10636 2/20 0.31
▸ NR1H2 P55055 2/20 0.31
▸ BUB1 O43683 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ CTSK P43235 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24661684 0.83 MEN1 (0.32) USP30KDM1AUSP2SMN1; SMN2MEN1
SCHEMBL22983952 0.81 P2RX7 (0.42) P2RX7
SCHEMBL25840896 0.80 USP30 (0.38) USP30KDM1AUSP2SMN1; SMN2PRMT5
SCHEMBL30051523 0.78 P2RX7 (0.44) USP30P2RX7USP2SMN1; SMN2MEN1
SCHEMBL24364813 0.78 USP30 (0.39) USP30KDM1AAAK1BUB1
SCHEMBL25037259 0.77 USP30 (0.39) USP30KDM1AAAK1BUB1BACE1
SCHEMBL25317580 0.74 USP30 (0.35) USP30KDM1AAAK1BUB1
SCHEMBL21516089 0.73 USP2 (0.38) KDM1AUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL520363 0.72 USP30 (0.42) USP30P2RX7USP2SMN1; SMN2MEN1
SCHEMBL29023102 0.71 USP30 (0.37) USP30KDM1AUSP2SMN1; SMN2PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709712-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF Blueprint Medicines Corporation (US) 2026-03-18 — — EP disclosed
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-10-30 — — US disclosed
US-12384778-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2025-08-12 — — US disclosed
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2025-07-31 — — US disclosed
EP-4573096-A1 INHIBITORS OF MYELOPEROXIDASE Astrazeneca AB (SE) 2025-06-25 — — EP disclosed
WO-2025125811-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Ontrack Therapeutics Limited (GB) 2025-06-19 — — WO disclosed
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2025-05-27 — — US disclosed
CN-119894896-A Inhibitors of green peroxidase 阿斯利康(瑞典)有限公司 2025-04-25 — — CN disclosed
WO-2024233900-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF BLUEPRINT MEDICINES CORPORATION (US) 2024-11-14 — — WO disclosed
US-20240368127-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, INC. 2024-11-07 — — US disclosed
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-19 — — US disclosed
US-20190322671-A1 CXCR4 INHIBITORS AND USES THEREOF X4 PHARMACEUTICALS, INC. 2019-10-24 — — US disclosed
US-10435405-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-10-08 — — US disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 — — US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 — — US disclosed
US-20180291014-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-10-11 — — US disclosed
EP-3356360-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF Genentech, Inc. (US) 2018-08-08 — — EP disclosed
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed
WO-2018049152-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 — — WO disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384778-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 USP30 3969/4885P2RX7 1421/4885KDM1A 3395/4885
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 USP30 3969/4885P2RX7 1421/4885KDM1A 3395/4885
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors CDK2, CDK4, CDK2AP2 USP30 3297/4885P2RX7 3500/4885KDM1A 1982/4885
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 USP30 3819/4885P2RX7 1893/4885KDM1A 3407/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 USP30 3969/4885P2RX7 1421/4885KDM1A 3395/4885
US-20190322671-A1 CXCR4 INHIBITORS AND USES THEREOF CXCR4, CXCL12, CXCR3 USP30 3774/4885P2RX7 33/4885KDM1A 4012/4885
US-20180291014-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF AVPR1B, C3AR1, RHEB USP30 4098/4885P2RX7 433/4885KDM1A 2269/4885
US-10435405-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 USP30 3969/4885P2RX7 1421/4885KDM1A 3395/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 USP30 3969/4885P2RX7 1421/4885KDM1A 3395/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 USP30 3969/4885P2RX7 1421/4885KDM1A 3395/4885
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL USP30 1544/4885P2RX7 2270/4885KDM1A 3175/4885
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 USP30 3297/4885P2RX7 3500/4885KDM1A 1982/4885
US-20240368127-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B11, HSD17B1 USP30 1398/4885P2RX7 4643/4885KDM1A 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.